A novel nomogram based on cardia and chemotherapy to predict postoperative overall survival of gastric cancer patients

Hanjun Mo (✉ hjmo18@fudan.edu.cn)  
Zhongshan Hospital Fudan University  
https://orcid.org/0000-0001-8912-4701

Pengfei Li  
Zhongshan Hospital Fudan University

Sunfang Jiang  
Zhongshan Hospital Fudan University

Research Article

Keywords: nomogram, gastric cancer, overall survival, SEER

DOI: https://doi.org/10.21203/rs.3.rs-453884/v1

License: ☑️ ️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** We aimed to establish and externally validate a nomogram to predict the 3- and 5-year overall survival (OS) of gastric cancer (GC) patients after surgical resection and explored the roles of cardia and chemotherapy.

**Methods:** A total of 6543 patients diagnosed with primary GC during 2004-2016 were collected from the Surveillance, Epidemiology and End Results (SEER) database. We grouped patients diagnosed during 2004-2012 into a training set (n=4528) and those diagnosed during 2013-2016 into an external validation set (n=2015). A nomogram was constructed after univariate and multivariate analysis. Performance was evaluated by Harrell’s C-index, area under the receiver operating characteristic curve (AUC), decision curve analysis (DCA), and calibration plot.

**Results:** The multivariate analysis identified age, race, location, tumor size, T stage, N stage, M stage, and chemotherapy as independent prognostic factors. In multivariate analysis, the hazard ratio (HR) of non-cardia was 0.762 (P<0.001), and that of chemotherapy was 0.556 (P<0.001). Our nomogram was found to exhibit excellent discrimination: in the training set, Harrell’s C-index was superior to that of the 8th American Joint Committee on Cancer (AJCC) TNM classification (0.736 vs 0.699, P<0.001); the C-index was also better in the validation set (0.748 vs 0.707, P<0.001). The AUCs for 3- and 5-year OS were 0.806 and 0.815 in the training set and 0.775 and 0.783 in the validation set, respectively. The DCA and calibration plot of the model also shows good performance.

**Conclusions:** We established a well-designed nomogram to accurately predict the OS of primary GC patients after surgical resection. We also further confirmed the prognostic value of cardia and chemotherapy in predicting the survival rate of GC patients.

Introduction

Gastric cancer (GC) remains the fifth most common cancer and the third main cause of cancer-related death, following lung cancer and colorectal cancer in both sexes [1]. More than one million people are diagnosed with GC annually, and the death toll is close to 800,000 [1]. The incidence among males is 2- to 3-fold higher than that among females (32.1 vs 13.2, per 100,000) in Eastern Asia, whereas the rate in Northern America is generally low [1].

GC can be classified as cardia and non-cardia, which have different epidemiology and causes [2, 3]. The incidence of non-cardia GC has declined over the past 30 years; however, cardia GC rates have remained stable or even increased [2, 4, 5]. The poor prognosis of cardia GC compared to non-cardia has been reported [6, 7], but whether cardia GC is an independent prognostic factor remains unknown.

Surgery is still the primary treatment to advanced gastric cancer (AGC), in which D2 lymphadenectomy has been widely carried out in Asia [8]. A study from Japan of the 118,367 patients after surgical resection showed the 5-year OS rate is 71.1% [9]. However, recurrence occurs in approximately 20-50% of
all patients after surgery [10]. Therefore, identifying prognostic factors is indispensable in choosing treatment methods and surveillance strategies.

A nomogram is a useful predictive tool for cancer due to its accuracy, practicability, and good discrimination. It can quantify individual’s survival rate in graphic form and has been used for many tumors [11-13]. The classic nomogram for GC is the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram created in 2003 [14]. Compared with the traditional staging system—the American Joint Committee on Cancer (AJCC) TNM classification, a nomogram incorporates more demographic and clinicopathologic factors into the model.

The 8\textsuperscript{th} AJCC staging system was effective in 2018, but few studies have compared nomograms with this new edition. In addition, the role of chemotherapy in the prognosis of GC has been mentioned, but no nomograms have included chemotherapy as a variable to date [8, 15]. Finally, most of the established nomograms for GC are complicated or internally validated, or they have a small training set [8, 10, 15-17]. Consequently, we aim to establish and externally validate a relatively simple, generalized nomogram to predict the overall survival (OS) of primary GC patients after surgical resection. We hope to determine the value of identifying GC as cardia versus non-cardia while exploring the role of adjuvant chemotherapy. The performance of the nomogram is also compared with the AJCC 8\textsuperscript{th} staging system.

Materials And Methods

Patients and Data Set

Data from patients diagnosed with primary GC during 2004-2016 were collected from the SEER 18 Regs Custom Data Set (with additional treatment fields, Nov 2018 Sub), covering approximately 27.8% of the US population [18]. The identification of GC patients was based on ICD-O-3/WHO 2008 histology codes. TNM staging was recoded according to the 8\textsuperscript{th} AJCC TNM classification. The inclusion criteria were as follows: primary GC after surgical resection; no other malignancies; positive histology affirmation; no preoperative radiotherapy; examined lymph nodes (LNs) more than 16; and complete clinical data without missing values. The detailed enrollment process is presented in Figure 1. Types of overlapping lesions or unspecified lesions were excluded. Finally, a total of 6543 cases with complete clinical data were included in our study. We grouped them into a training set (n=4528) and an external validation set (n=2015) according to year at diagnosis (2004-2012 and 2013-2016, respectively). Comparisons of demographic and clinicopathologic variables between the training and validation sets were generated using the “table1” function in R software.

Construction of the Nomogram

The cutoff values of continuous variables were determined using X-tile software designed by the Yale School of Medicine and our clinical experience. We divided patients into two groups according to age (<70 or \(\geq\) 70 years) and into three groups according to tumor size (<2 cm, 2-10 cm, or \(\geq\) 10 cm/diffuse). In variable of race (ethnicity), “other” included American Indian/AK Native and Asian/Pacific Islander. The
SEER database classifies tumor histology (grade) into 4 groups: well differentiated (grade I), moderately differentiated (grade II), poorly differentiated (grade III), and undifferentiated/anaplastic (grade IV). We integrated poorly differentiated and undifferentiated/anaplastic tumors into a single group (“Poorly”). Location was further stratified into cardia and non-cardia (including fundus, body, antrum and pylorus, lesser and greater curvature).

After univariate and multivariate analyses, independent prognostic factors were identified by the forward stepwise selection method. The proportional hazards (PH) assumption was examined before the multivariate analysis to ensure that the variables fitted to the PH assumption. When \( P < 0.1 \) in the univariate analysis, the variables were further analyzed with the Cox proportional hazards (PH) regression model. A nomogram was then constructed to predict 3- and 5-year OS for primary GC patients after surgery. Kaplan-Meier (KM) survival curves were constructed and compared with the log-rank test.

**Nomogram Performance**

Our nomogram performance was evaluated by discrimination and calibration of both the training and validation sets. Discrimination was evaluated using Harrell's C-index. The principle of the C-index has been described by Han et al [8]. The \( P \) value comparison of our nomogram with the AJCC staging system was achieved using the “compareC” function in R software. The prediction was further evaluated by the area under the receiver operating characteristic (ROC) curve (AUC) and the net benefit of decision curve analysis (DCA). Calibration was carried out by comparing the means of the nomogram-predicted survival rate with the actual OS measured by the KM method. Bootstraps were set to 1000 reiterations. Predicted total points were added as a new variable to the established nomogram in order to achieve external validation. Calibration plots of 3- and 5-year survival in the training set and 3-year survival in the validation set were constructed.

**Statistical Analysis**

Statistical analysis was performed using SPSS version 22.0 (SPSS, Chicago, IL, USA) and R software version 4.0.1 via rms, survival, table1, compareC, and ggplot2 packages. All tests were two-sided, and a \( P \) value<0.05 was considered statistically significant. This study did not require local ethics approval.

**Results**

**Patient Characteristics**

Demographic and clinicopathologic characteristics are presented in Table 1. The median age at diagnosis in both sets was 66 years, and male patients were the majority (60.5% and 61.3%, respectively). Cardia GC accounted for approximately one-fourth (25.1%) of the whole GC population in the training set. Most of the patients (approximately 70%) had poorly differentiated disease, and more than 60% had stage II or III disease. The median numbers of examined LNs were 23 (range: 19-31) and 24 (range: 19-
33) in the training and validation sets, respectively. Approximately one-third of the patients received radiotherapy, and half received chemotherapy.

Analysis and Development of the Nomogram

Selected variables and hazard ratios (HRs) after univariate and multivariate analyses are listed in Table 2. We identified age, race, location, T stage, N stage, M stage, tumor size, and chemotherapy as independent prognostic factors associated with OS for GC patients. Due to a lack of significance, sex was excluded from the Cox PH regression model (HR: 0.973, 95% CI: 0.903-1.049).

Among the patients included in our research, HRs were found to be significantly higher for individuals who had the following characteristics: older than 70, male, black, cardia, poorly differentiated disease, deeper invasion, more LN metastasis, distant metastasis, larger tumor size, and no chemotherapy. Of note, after adjustment for the multivariate analysis, the HR for location was 0.762 (95% CI: 0.699-0.831, \( P < 0.001 \)), indicating that the non-cardia type is an independent protective factor for GC prognosis. There are two distinct discrepancies between the univariate and multivariate analyses. Although grade was statistically significant in the univariate analysis, it seemed to be nonsignificant when adjusted by the multivariate model. Considering that grade represents histologic differentiation and is of clinical value, we still included it in the model. For chemotherapy, no significant difference was observed in the univariate analysis (HR: 0.936, 95% CI: 0.870-1.006, \( P = 0.073 \)). However, in the multivariate analysis, the difference was significant (HR: 0.556, 95% CI: 0.513-0.602, \( P < 0.001 \)). The KM survival curves of select factors are shown in Figures 2 and 3. In each panel of Figure 2, the curves show good prognostic stratification for selected variables. As shown in Figure 3, postoperative chemotherapy significantly prolonged patient survival after adjustment for the Cox PH model.

The nomogram used to predict 3- and 5-year OS is shown in Figure 4. First, draw a vertical line to the top point of the scale for each variable and then add up the points. The sum of the scores aligned to the bottom scales indicate the 3- and 5-year OS. From Figure 4, we can see that N stage accounts for a large proportion of the total scores, indicating that the number of metastatic LNs is the most critical prognostic factor for GC. Patients with cardia GC receive nearly 20 points, and those who do not undergo chemotherapy receive approximately 40 points.

Performance of the Nomogram

Our nomogram exhibits excellent discrimination ability. In the training set (Table 3), the C-index was 0.736 (95% CI, 0.726-0.746), which was superior to that of the 8\textsuperscript{th} AJCC TNM classification (C-index, 0.699; 95% CI, 0.689-0.709, \( P < 0.001 \)). In the validation set, the C-index was also better than that of the AJCC staging system [0.748 vs 0.707; 95% CI, (0.726-0.770) vs (0.684-0.730), \( P < 0.001 \)]. In addition, the ROCs of the nomogram exhibited great predictive ability in both the training and validation sets, with AUCs of 0.806 and 0.815 at 3 years and 5 years in the training set, respectively (Figure 5A, 5B). In the validation set (Figure 5C, 5D), the AUCs were only slightly reduced (0.775 and 0.783 for 3- and 5-year OS, respectively). The DCA results further demonstrated the performance of our nomogram (Figure 6). Regardless of
whether the training (Figure 6A, 6C) or validation set (Figure 6B, 6D) is used, our nomogram had a larger net benefit than the AJCC TNM classification. This favorable effect remains across a threshold probability of 0.05 to 0.45 for 3 years and 0.6 for 5 years.

The calibration plots also showed good agreement of the nomogram-predicted 3- and 5-year survival in the training set and 3-year survival in the validation set (Figure 7). The 5-year curve in the validation set cannot be constructed because of the short follow-up time (patients were diagnosed during 2013-2016). The diagonal line represents the ideal situation, and we can see that the predicted survival corresponds closely with the actual OS.

Discussion

In the current study, we developed and externally validated a nomogram to predict 3- and 5-year OS for primary GC patients after surgical resection. We identified age, race, location, tumor size, T stage, N stage, M stage, and chemotherapy as independent prognostic factors, among which the number of metastatic LNs held the most weight. Compared with the 8th AJCC TNM classification, our nomogram performed better in both the training and external validation sets. To some extent, the 8th AJCC staging system did not perform poorly. Nevertheless, our nomogram can predict individualized survival probability more precisely.

Some nomograms classified GC location into the upper, middle, and lower third [8, 15]. In this study, we divided all GC types into cardia and non-cardia (the survival curves of the middle third and lower third were similar in our cohort; data not shown). As a result, we found that cardia GC had a worse prognosis than non-cardia GC (P<0.001). Our finding is consistent with a systematic review that found patients with upper third GC had significantly increased all-cause mortality [19]. When the gastroesophageal junction (GEJ) was removed, the prognosis of pure cardia GC was even worse. Our data also show that sex was not an independent prognostic factor, which is inconsistent with previous findings [8, 10, 14, 15, 20]. Although males and females differ in terms of incidence rate, their prognoses appear to be similar.

Previously, Kim et al. found that age had nonlinear effects on HR [10]. Another study also found that patients older than 70 years had the lowest 5-year OS compared with younger and middle-aged patients [21]. Their results are consistent with our analysis using X-tile software, so we chose to convert age into a categorical variable at 70. Although grade is closely associated with malignant behavior and distant metastasis, it does not seem to be an independent factor affecting prognosis in our study. Therefore, when we performed multivariate analysis, the P value became insignificant.

Another discrepancy in this study pertains to chemotherapy. Recent studies have proven that adjuvant chemotherapy after surgery could benefit patients in terms of survival probability [22]. A meta-analysis showed that compared with surgery alone, fluorouracil-based postoperative adjuvant chemotherapy significantly reduced the mortality of GC patients [23]. Another phase III randomized controlled trial (RCT) revealed that chemotherapy using capecitabine plus oxaliplatin for half a year after D2 gastrectomy
improved the 3-year disease-free survival of GC compared with surgery alone (74% vs 59%, HR: 0.56, \( P<0.001 \)) [24]. The results of our multivariate analysis further demonstrated that chemotherapy acted as a protective factor against poor outcomes (Figure 3). We believe its failure to show statistical significance in the univariate analysis was largely due to some confounding factors. To the best of our knowledge, we are the first to finally include chemotherapy in the nomogram construction of GC.

Similar to most previous studies, we excluded patients with fewer than 16 examined LNs [8]. This helps to ensure surgical quality and prevent the stage migration effect [8, 25]. In our study, the median examined LN numbers were 23 and 24 in the training and validation sets, respectively.

Quite a few studies have used a randomly assigned (data-splitting) method to create a validation set [8, 16, 17]. However, this method theoretically is more of internal validation and will lead to sample wasting as well as insufficient power for evaluation. In contrast, our external validation set was established according to year at diagnosis (training set, 2004-2012; validation set, 2013-2016). In the calibration plot, the predicted survival corresponded closely with the actual 3- and 5-year OS (Figure 6).

Notably, 655 patients had distant metastasis (M1) but underwent surgery. Among them, 58.6% (384/655) received chemotherapy, and 15.1% (99/655) received radiotherapy. A growing number of studies have shown that patients with unresectable stage IV GC can achieve good survival outcomes if they undergo radical gastrectomy after responding to several combined chemotherapy regimens [26]. This novel strategy is called conversion surgery, a treatment approach in which initially unresectable tumors become curable after chemotherapy response. If R0 resection is achieved, conversion surgery can significantly improve the patient survival rate [26]. We thus did not exclude such patients and hope that our nomogram can be used with these patients to predict OS after surgery. Nevertheless, this concept is still controversial, and current cancer guidelines do not recommend surgery for stage IV patients.

Regarding the surgical approach, one study revealed that distal gastrectomy had comparable long-term survival to total gastrectomy for middle and lower third GC when R0 resection was achieved [27]. Apart from conventional open surgery, laparoscopic gastrectomy has also been performed in recent years [28]. RCTs comparing laparoscopic with open distal gastrectomy showed that the former had noninferior 3-year survival in both early and advanced GC [29, 30]. For early gastric cancer (EGC), endoscopic treatments such as endoscopic submucosal dissection (ESD) are becoming increasingly popular, with advantages of minimized invasion and low postoperative complications [31]. Researchers in Japan analyzed 1956 patients with EGC undergoing curative ESD and found that the 5-year OS rate was 92.6% [31]. Another study predicting the risk of lymph node metastasis (LNM) in EGC after radical ESD suggested that a predicted risk of less than 3% may avoid subsequent gastrectomy, which could ultimately improve patient quality of life.

There are some striking strengths in our study. First, we used the SEER database, a standardized and relatively comprehensive database with a large sample size. Data from 2004 were collected, and more than 6000 patients were ultimately included in our study. Second, to the best of our knowledge, we are the first to classify GC according to cardia/non-cardia in a nomogram and found good discrimination in
survival outcomes. We are also the first to finally include chemotherapy in the nomogram for GC as an independent prognostic factor. Third, our nomogram is based on the existing 8th AJCC staging system; thus, it is widely available and highly convenient for clinical application. The performance of our nomogram was excellent, with a C-index of 0.748 in the external validation set.

Our study also has some limitations that should be noted. First, patients who did not receive chemotherapy and those with missing information were included in the SEER database, which added difficulty in determining the significance of chemotherapy. However, the actual role of chemotherapy in patient prognosis could be underestimated because of this limitation. Second, we did not further divide T4 and N3 stages in our results because 893 cases had T4 or N3 stage but lacked specific details. This may have sacrificed some precision but simplified the model.

Conclusion

In summary, we established and externally validated an elaborate nomogram to predict 3- and 5-year OS for primary GC after surgical resection. We believe that our nomogram can provide precise predictions in Western populations. Future studies are needed to further evaluate its performance and extend its applicability.

Abbreviations

SEER: Surveillance, Epidemiology, and End Results; AJCC: American Joint Committee on Cancer; GC: gastric cancer; OS: overall survival; HR: hazard ratio; LN: Lymph Node; TNM: tumor-node-metastasis; ROC: receiver operating characteristic; AUC: area under receiver operating character curve; DCA: decision curve analysis.

Declarations

Acknowledgments

The authors would like to thank the Surveillance, Epidemiology, and End Results (SEER) Research Database (1975-2016) of National Cancer Institution. We acknowledged the funding support by the Program for Shanghai Outstanding Medical Academic Leader (2019LJ15) and Scientific Research Project of Shanghai Science and Technology Commission (17ZR1404900).

Author contributions

Conception and design: Hanjun Mo, Pengfei Li, Sunfang Jiang; Data collection, analysis and interpretation: Hanjun Mo, Pengfei Li; Manuscript writing: Hanjun Mo; Review and editing: Hanjun Mo, Pengfei Li, Sunfang Jiang; Administrative support: Sunfang Jiang; Final approval of manuscript: All authors.
Funding

The study was supported by the Program for Shanghai Outstanding Medical Academic Leader (2019LJ15) and Scientific Research Project of Shanghai Science and Technology Commission (17ZR1404900).

Availability of data and materials

The datasets supporting our conclusion can be acquired from SEER database (https://seer.cancer.gov/). All R codes used in this study can be accessed via Github (https://github.com/wdxmo/nomogram/find/main).

Ethics approval and consent to participate

All the data were accessed from the public SEER database and no ethical approval was required.

Consent for publication

Not applicable

Competing interests

The authors declare that there is no conflict of interest.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018; 68: 394-424.

2. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014; 23: 700-13.

3. Gupta S, Tao L, Murphy JD, Camargo MC, Oren E, Valasek MA, et al. Race/Ethnicity-, Socioeconomic Status-, and Anatomic Subsite-Specific Risks for Gastric Cancer. Gastroenterology. 2019; 156: 59-62.e4.

4. Corley DA, Kubo A. Influence of site classification on cancer incidence rates: an analysis of gastric cardia carcinomas. Journal of the National Cancer Institute. 2004; 96: 1383-7.

5. Anderson WF, Camargo MC, Fraumeni JF, Jr., Correa P, Rosenberg PS, Rabkin CS. Age-specific trends in incidence of noncardia gastric cancer in US adults. Jama. 2010; 303: 1723-8.

6. Kim YJ, Chung WC, Cho IH, Kim J, Kim S. Prognostic effect of different etiologies in patients with gastric cardia cancer. Medicine. 2019; 98: e18397.
7. Zhao J, Zhao J, Du F, Zhang Y, Shen G, Zhu H, et al. Cardia and Non-Cardia Gastric Cancer Have Similar Stage-for-Stage Prognoses After R0 Resection: a Large-Scale, Multicenter Study in China. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2016; 20: 700-7.

8. Han DS, Suh YS, Kong SH, Lee HJ, Choi Y, Aikou S, et al. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012; 30: 3834-40.

9. Katai H, Ishikawa T, Akazawa K, Isobe Y, Miyashiro I, Oda I, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2018; 21: 144-54.

10. Kim Y, Spolverato G, Ejaz A, Squires MH, Poultsides G, Fields RC, et al. A nomogram to predict overall survival and disease-free survival after curative resection of gastric adenocarcinoma. Annals of surgical oncology. 2015; 22: 1828-35.

11. Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31: 1188-95.

12. Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010; 28: 3762-9.

13. Liang W, Zhang L, Jiang G, Wang Q, Liu L, Liu D, et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015; 33: 861-9.

14. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003; 21: 3647-50.

15. Hirabayashi S, Kosugi S, Isobe Y, Nashimoto A, Oda I, Hayashi K, et al. Development and external validation of a nomogram for overall survival after curative resection in serosa-negative, locally advanced gastric cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2014; 25: 1179-84.

16. Yu C, Zhang Y. Development and validation of prognostic nomogram for young patients with gastric cancer. Annals of translational medicine. 2019; 7: 641.

17. Song KY, Park YG, Jeon HM, Park CH. A nomogram for predicting individual survival of patients with gastric cancer who underwent radical surgery with extended lymph node dissection. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2014; 17: 287-93.
18. Hu P, Bai J, Liu M, Xue J, Chen T, Li R, et al. Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2020; 23: 591-9.

19. Petrelli F, Ghidini M, Barni S, Steccanella F, Sgroi G, Passalacqua R, et al. Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies. Annals of surgical oncology. 2017; 24: 2655-68.

20. Zheng ZF, Lu J, Wang W, Desiderio J, Li P, Xie JW, et al. Development and External Validation of a Simplified Nomogram Predicting Individual Survival After R0 Resection for Gastric Cancer: An International, Multicenter Study. Annals of surgical oncology. 2018; 25: 2383-90.

21. Liang YX, Deng JY, Guo HH, Ding XW, Wang XN, Wang BG, et al. Characteristics and prognosis of gastric cancer in patients aged ≥ 70 years. World journal of gastroenterology. 2013; 19: 6568-78.

22. Oh DY, Bang YJ. Adjuvant and neoadjuvant therapy for gastric cancer. Current treatment options in oncology. 2013; 14: 311-20.

23. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. Jama. 2010; 303: 1729-37.

24. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (London, England). 2012; 379: 315-21.

25. Kong SH, Lee HJ, Ahn HS, Kim JW, Kim WH, Lee KU, et al. Stage migration effect on survival in gastric cancer surgery with extended lymphadenectomy: the reappraisal of positive lymph node ratio as a proper N-staging. Annals of surgery. 2012; 255: 50-8.

26. Zhang F, Huang X, Song Y, Gao P, Zhou C, Guo Z, et al. Conversion Surgery for Stage IV Gastric Cancer. Frontiers in oncology. 2019; 9: 1158.

27. Li Z, Bai B, Xie F, Zhao Q. Distal versus total gastrectomy for middle and lower-third gastric cancer: A systematic review and meta-analysis. International journal of surgery (London, England). 2018; 53: 163-70.

28. Kinoshita T, Uyama I, Terashima M, Noshiro H, Nagai E, Obama K, et al. Long-term Outcomes of Laparoscopic Versus Open Surgery for Clinical Stage II/III Gastric Cancer: A Multicenter Cohort Study in Japan (LOC-A Study). Annals of surgery. 2019; 269: 887-94.

29. Yu J, Huang C, Sun Y, Su X, Cao H, Hu J, et al. Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. Jama. 2019; 321: 1983-92.

30. Kim HH, Han SU, Kim MC, Kim W, Lee HJ, Ryu SW, et al. Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial. JAMA oncology. 2019; 5: 506-13.

31. Suzuki H, Oda I, Abe S, Sekiguchi M, Mori G, Nonaka S, et al. High rate of 5-year survival among patients with early gastric cancer undergoing curative endoscopic submucosal dissection. Gastric
cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2016; 19: 198-205.

Tables

Table 1 Demographic and clinicopathologic variables of the training and validation sets
| Variable                  | Training Set (n=4528) | Validation Set (n=2015) | P-value |
|--------------------------|-----------------------|-------------------------|---------|
|                          | n                     | %                       | n       | %       |
| Age (years)              |                       |                         |         |         |
| Median (Range)           | 66 (55-75)            | 66 (56-74)              | 0.644   |
| <70                      | 2748                  | 60.7                    | 1226    | 60.8    |
| ≥70                      | 1780                  | 39.3                    | 789     | 39.2    |
| Sex                      |                       |                         | 0.556   |
| Male                     | 2741                  | 60.5                    | 1236    | 61.3    |
| Female                   | 1787                  | 39.5                    | 779     | 38.7    |
| Race                     |                       |                         | 0.004   |
| White                    | 2787                  | 61.6                    | 1156    | 57.4    |
| Black                    | 568                   | 12.5                    | 263     | 13.1    |
| Other                    | 1173                  | 25.9                    | 596     | 29.6    |
| Location                 |                       |                         | <0.001  |
| Cardia                   | 1135                  | 25.1                    | 364     | 18.1    |
| Non-cardia               | 3393                  | 74.9                    | 1651    | 81.9    |
| Grade (Histology)        |                       |                         | 0.007   |
| Well                     | 155                   | 3.4                     | 102     | 5.1     |
| Moderately               | 1106                  | 24.4                    | 483     | 24.0    |
| Poorly                   | 3267                  | 72.2                    | 1430    | 71.0    |
| AJCC 8th Stage           |                       |                         | <0.001  |
| I                        | 1109                  | 24.5                    | 517     | 25.7    |
| II                       | 1513                  | 33.4                    | 501     | 24.9    |
| III                      | 1401                  | 30.9                    | 846     | 42.0    |
| IV                       | 505                   | 11.2                    | 151     | 7.5     |
| T stage                  |                       |                         | <0.001  |
| T1                       | 736                   | 16.3                    | 448     | 22.2    |
| T2                       | 1676                  | 37.0                    | 251     | 12.5    |
| T3                       | 1407                  | 31.1                    | 727     | 36.1    |
|                |          |       |       |       |
|----------------|----------|-------|-------|-------|
| T4             | 709      | 15.7  | 589   | 29.2  |
| N stage        | <0.001   |       |       |       |
| N0             | 1274     | 28.1  | 717   | 35.6  |
| N1             | 1176     | 26.0  | 359   | 17.8  |
| N2             | 1054     | 23.3  | 353   | 17.5  |
| N3             | 1024     | 22.6  | 586   | 29.1  |
| M stage        | <0.001   |       |       |       |
| M0             | 4023     | 88.8  | 1865  | 92.6  |
| M1             | 505      | 11.2  | 150   | 7.4   |
| Tumor size (cm)| <0.001   |       |       |       |
| <2             | 476      | 10.5  | 328   | 16.3  |
| 2-10           | 3620     | 79.9  | 1532  | 76.0  |
| ≥10/diffuse    | 432      | 9.5   | 155   | 7.7   |
| Examined LNs (No.) | <0.001 |       |       |       |
| Median (Range) | 23 (19-31)| 24 (19-33)|       |       |
| Radiation      | <0.001   |       |       |       |
| No radiation or surgery | 3029 | 66.9  | 1526  | 75.7  |
| Yes            | 1499     | 33.1  | 489   | 24.3  |
| Chemotherapy   | <0.001   |       |       |       |
| No/Unknown     | 2167     | 47.9  | 873   | 43.3  |
| Yes            | 2361     | 52.1  | 1142  | 56.7  |

Abbreviations: LN, lymph node; AJCC, American Joint Committee on Cancer

**Table 2** Variables associated with OS according to the Cox PH regression model
| Variable      | Univariable analysis |                | Multivariable analysis |                |
|---------------|----------------------|----------------|------------------------|----------------|
|               | HR       | 95% CI     | *P*-value  | HR       | 95% CI     | *P*-value  |
| Age, years    |          |            |            |          |            |            |
| <70           | Ref      |            |            | Ref      |            |            |
| ≥70           | 1.526    | 1.419-1.642| <0.001     | 1.671    | 1.546-1.806| <0.001     |
| Sex           |          |            |            |          |            |            |
| Male          | Ref      |            |            | Ref      |            |            |
| Female        | 0.973    | 0.903-1.049| 0.476      |          |            |            |
| Race          |          |            |            |          |            |            |
| White         | Ref      |            |            | Ref      |            |            |
| Black         | 1.043    | 0.934-1.163| 0.456      | 1.079    | 0.965-1.207| 0.183      |
| Other         | 0.806    | 0.738-0.880| <0.001     | 0.857    | 0.783-0.939| 0.001      |
| Location      |          |            |            |          |            |            |
| Cardia        | Ref      |            |            | Ref      |            |            |
| Non-cardia    | 0.906    | 0.835-0.983| 0.018      | 0.762    | 0.699-0.831| <0.001     |
| Grade         |          |            |            |          |            |            |
| Well          | Ref      |            |            | Ref      |            |            |
| Moderately    | 1.515    | 1.182-1.942| 0.001      | 0.972    | 0.756-1.249| 0.824      |
| Poorly        | 2.064    | 1.624-2.623| <0.001     | 1.153    | 0.902-1.474| 0.257      |
| T stage       |          |            |            |          |            |            |
| T1            | Ref      |            |            | Ref      |            |            |
| T2            | 2.903    | 2.515-3.349| <0.001     | 2.04     | 1.741-2.389| <0.001     |
| T3            | 3.896    | 3.371-4.504| <0.001     | 2.265    | 1.919-2.674| <0.001     |
| T4            | 5.31     | 4.547-6.201| <0.001     | 2.683    | 2.242-3.210| <0.001     |
| N stage       |          |            |            |          |            |            |
| N0            | Ref      |            |            | Ref      |            |            |
| N1            | 2.051    | 1.828-2.302| <0.001     | 1.981    | 1.749-2.243| <0.001     |
| N2            | 3.527    | 3.147-3.952| <0.001     | 3.308    | 2.912-3.758| <0.001     |
| N3            | 5.446    | 4.861-6.102| <0.001     | 4.431    | 3.876-5.065| <0.001     |
M stage

| M stage | Ref | Ref |
|---------|-----|-----|
| M0      | 2.891 | 2.611-3.200 | <0.001 |
| M1      | 1.888 | 1.698-2.099 | <0.001 |

Tumor size, mm

| Tumor size, mm | Ref | Ref |
|----------------|-----|-----|
| <2             | 2.477 | 2.122-2.892 | <0.001 |
| 2~10           | 1.158 | 0.980-1.369 | 0.085 |
| ≥10/diffuse    | 4.632 | 3.861-5.558 | <0.001 |

Chemotherapy

| Chemotherapy | Ref | Ref |
|--------------|-----|-----|
| No/Unknown   | 0.936 | 0.870-1.006 | 0.073 |
| Yes          | 0.556 | 0.513-0.602 | <0.001 |

Abbreviations: HR hazard ratio; CI confidence interval; Ref reference

**Table 3** C-indexes for the nomogram and the AJCC 8th staging system in GC patients

| OS | Training set | Validation set |
|----|--------------|----------------|
|    | C-index       | P-value        | C-index       | P-value        |
|    | (95% CI)      |                | (95% CI)      |                |
| Nomogram | 0.736 (0.726-0.746) | 0.748 (0.726-0.770) | 0.707 (0.684-0.730) | <0.001 |
| 8th AJCC stage | 0.699 (0.689-0.709) | <0.001 | 0.707 (0.684-0.730) | <0.001 |

Abbreviations: AJCC, American Joint Committee on Cancer; GC, gastric cancer; OS, overall survival; CI, confidence interval

**Figures**
Figure 1

Flow chart of patient characteristics according to inclusion and exclusion criteria. Abbreviations: SEER, Surveillance, Epidemiology and End Results; LN, lymph node; TNM, tumor-node-metastasis.
Figure 2

Kaplan-Meier survival curves of the independent prognostic factors (A-E, G-I) and TNM classification (F). The horizontal dotted line indicates the median survival time (OS=0.5); the vertical line indicates the time at 3 and 5 years. Abbreviations: AJCC, American Joint Committee on Cancer.
Figure 3

Kaplan-Meier survival curves of chemotherapy (A) and chemotherapy after adjusted (B)
Figure 4

Nomogram predicting 3- and 5-year OS after surgical resection of GC
Figure 5

Receiver operating characteristic (ROC) curves predicting OS (A) 3-year in the training set; (B) 5-year in the training set; (C) 3-year in the validation set; (D) 5-year in the validation set. Abbreviations: AUC, area under the receiver operating characteristic curve.
Figure 6

Decision curve analysis (DCA) to evaluate our nomogram and AJCC TNM classification (A) 3-year and (B) 5-year in the training set; (B) 3-year and (D) 5-year in the validation set. Horizontal black line: no patients will die. Inclined gray line: all patients will die. Abbreviations: TNM, tumor-node-metastasis
Figure 7

Calibration curves predicting overall survival (A) 3-year in the training set; (B) 5-year in the training set; (C) 3-year in the validation set. The x-axis represents nomogram-predicted survival; the y-axis represents actual survival and 95% confidence intervals (CIs) measured by Kaplan-Meier analysis.